115 studies found for:    Open Studies | "Peritoneal Diseases"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Influence of Posture and Gas Insufflation on Perioperative Lung Function
Condition: Pneumoperitoneum
Intervention:
2 Recruiting EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
3 Recruiting Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
4 Recruiting IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis
Condition: Suspected Tuberculous Peritonitis
Intervention: Other: Blood and Ascites ELISPOT
5 Recruiting Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: RAD001;   Drug: bevacizumab
6 Recruiting Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec)
Conditions: Primary Peritoneal Neoplasm;   Secondary Peritoneal Neoplasm
Interventions: Drug: Goal Directed Intravenous Restrictive Fluid Therapy;   Drug: Conventional Intravenous Fluid therapy
7 Unknown  Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Other: flow cytometry;   Other: immunohistochemistry staining method
8 Unknown  Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections
Condition: Secondary or Tertiary Peritonitis
Intervention:
9 Recruiting A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: MEK162, MEK inhibitor; oral;   Drug: Paclitaxel, mitotic inhibitor; intravenous
10 Recruiting Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cavity Cancer
Intervention: Procedure: Tumor Debulking Surgery by laparoscopy
11 Not yet recruiting Cardiovascular Effects of the Degree of Head-down and Pneumoperitoneum During Laparoscopy
Condition: Laparoscopy
Intervention:
12 Recruiting Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
Conditions: Breast Neoplasms;   Peritoneal Neoplasms;   Ovarian Neoplasms;   Pancreatic Neoplasms;   Stomach Neoplasms
Interventions: Other: ²¹²Pb-TCMC-Trastuzumab;   Biological: trastuzumab
13 Unknown  Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
Conditions: Breast Cancer;   Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer;   Prostate Cancer;   Sarcoma;   Vaginal Cancer;   Vulvar Cancer
Interventions: Genetic: gene expression analysis;   Genetic: gene rearrangement analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Radiation: radiation therapy
14 Recruiting Phase II of Carbo/Pralatrexate in Rec. Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: carboplatin;   Drug: pralatrexate
15 Recruiting Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
Conditions: Ovarian Carcinoma;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Biological: OC-DC vaccine;   Drug: Bevacizumab;   Drug: cyclophosphamide  300 mg/m2/d for 3 days;   Drug: fludarabine 30 mg/m2/d for 3 days;   Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
16 Not yet recruiting An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Condition: Ovarian Cancer, Peritoneal Neoplasms
Intervention:
17 Recruiting GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: Ganetespib;   Drug: Paclitaxel
18 Recruiting Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis
Conditions: SBP;   Liver Cirrhosis
Interventions: Drug: Cefotaxime;   Drug: Ceftriaxone;   Drug: Ciprofloxacin
19 Unknown  Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
Conditions: Colorectal Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Procedure: hyperthermia treatment
20 Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Conditions: Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Drug: poly ICLC;   Drug: IDO1 inhibitor INCB024360;   Other: pharmacological study;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years